Literature DB >> 32712168

A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis.

Cihan Heybeli1, Andrew Bentall2, Jiqiu Wen3, Mariam Priya Alexander4, Francis K Buadi5, Fernando G Cosio2, Patrick G Dean6, Angela Dispenzieri5, David Dingli5, Mireille El Ters2, Morie A Gertz5, Amer Hatem2, Prashant Kapoor5, Hasan Khamash7, Taxiarchis Kourelis5, Shaji Kumar5, Elizabeth C Lorenz2, Martin Mai8, Eli Muchtar5, David L Murray9, Mikel Prieto6, Carrie A Schinstock2, Mark D Stegall6, Rahma Warsame5, Nelson Leung10.   

Abstract

Longer survival using modern therapies has increased the number of patients with immunoglobulin light-chain amyloidosis receiving kidney transplantation. We evaluated 60 patients with immunoglobulin light chain amyloidosis who underwent kidney transplantation based on their hematologic response for outcomes of death, graft failure, and complications. Patient hematologic responses (light-chain in blood or urine) prior to kidney transplantation were three patients had no response, five had a partial response, six had a very good partial response, 37 had a complete response, and nine were treatment-naive patients (never treated for this disorder). After transplantation, seven of nine treatment-naive patients achieved a complete response. The median follow-up for the entire transplant cohort was 61 months. The estimated median overall survival from the time of kidney transplantation was 123 months for the entire group. Median overall survival was not reached for the very good partial response plus complete response groups, it was 47 months for no response plus partial response groups, and 117 months for the treatment-naive group (all significantly different). Median overall survival of very good partial response was 81 months, while the median was not reached in the complete response group (no significant difference). The time to amyloid recurrence was significantly longer in complete response compared to very good partial response (median 181 vs 81 months). Death-censored graft survival at one- and five-years was 98.3%, and 95.8%, respectively for all groups. Of the 60 patients, three had allograft failure, 19 died with a functioning graft, and 13 had an amyloid recurrence. Thus, outcomes after kidney transplant in patients with immunoglobulin light-chain amyloidosis seem acceptable if a very good partial response or complete response is achieved either before or after transplantation.
Copyright © 2020 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  kidney transplantation; mass spectrometry; monoclonal gammopathy

Mesh:

Substances:

Year:  2020        PMID: 32712168      PMCID: PMC8411566          DOI: 10.1016/j.kint.2020.06.036

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  44 in total

1.  Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study.

Authors:  Angela Dispenzieri; Robert A Kyle; Martha Q Lacy; Terry M Therneau; Dirk R Larson; Matthew F Plevak; S Vincent Rajkumar; Rafael Fonseca; Philip R Greipp; Thomas E Witzig; John A Lust; Steven R Zeldenrust; Denise S Snow; Susan R Hayman; Mark R Litzow; Dennis A Gastineau; Ayalew Tefferi; David J Inwards; Ivana N Micallef; Stephen M Ansell; Luis F Porrata; Michelle A Elliott; Morie A Gertz
Journal:  Blood       Date:  2004-01-22       Impact factor: 22.113

2.  Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis.

Authors:  Giovanni Palladini; Paola Russo; Mario Nuvolone; Francesca Lavatelli; Vittorio Perfetti; Laura Obici; Giampaolo Merlini
Journal:  Blood       Date:  2007-07-15       Impact factor: 22.113

3.  Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients.

Authors:  Maria Teresa Cibeira; Vaishali Sanchorawala; David C Seldin; Karen Quillen; John L Berk; Laura M Dember; Adam Segal; Frederick Ruberg; Hans Meier-Ewert; Nancy T Andrea; J Mark Sloan; Kathleen T Finn; Gheorghe Doros; Joan Blade; Martha Skinner
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

Review 4.  New developments in diagnosis, risk assessment and management in systemic amyloidosis.

Authors:  Iuliana Vaxman; Angela Dispenzieri; Eli Muchtar; Morie Gertz
Journal:  Blood Rev       Date:  2019-11-02       Impact factor: 8.250

5.  Kidney transplantation in AL Amyloidosis: is it time to maximize access?

Authors:  Insara J Sathick; Cara A Rosenbaum; Victoria Gutgarts; Heather Landau
Journal:  Br J Haematol       Date:  2019-11-15       Impact factor: 6.998

6.  A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis.

Authors:  Giovanni Palladini; Ute Hegenbart; Paolo Milani; Christoph Kimmich; Andrea Foli; Anthony D Ho; Marta Vidus Rosin; Riccardo Albertini; Remigio Moratti; Giampaolo Merlini; Stefan Schönland
Journal:  Blood       Date:  2014-08-12       Impact factor: 22.113

7.  Outcome in renal Al amyloidosis after chemotherapy.

Authors:  Jennifer H Pinney; Helen J Lachmann; Loveleen Bansi; Ashutosh D Wechalekar; Janet A Gilbertson; Dorota Rowczenio; Prayman T Sattianayagam; Simon D J Gibbs; Emanuela Orlandi; Nancy L Wassef; Arthur R Bradwell; Philip N Hawkins; Julian D Gillmore
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

8.  Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factor.

Authors:  Tamer Rezk; Helen J Lachmann; Marianna Fontana; Sajitha Sachchithanantham; Shameem Mahmood; Aviva Petrie; Carol J Whelan; Jennifer H Pinney; Darren Foard; Thirusha Lane; Taryn Youngstein; Ashutosh D Wechalekar; Paul Bass; Philip N Hawkins; Julian D Gillmore
Journal:  Kidney Int       Date:  2017-07-18       Impact factor: 10.612

9.  The association of serum-free light-chain levels with markers of renal function.

Authors:  Bilge Karatoy Erdem; Fatih Davran; Vural Taner Yilmaz; Ramazan Çetinkaya; Halide Akbas
Journal:  Ren Fail       Date:  2015-06-09       Impact factor: 2.606

10.  Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis.

Authors:  Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Francis K Buadi; David Dingli; Suzanne R Hayman; Shaji K Kumar; Nelson Leung; John Lust; S Vincent Rajkumar; Stephen J Russell; Vera J Suman; Jennifer G Le-Rademacher; William J Hogan
Journal:  Cancer       Date:  2016-05-03       Impact factor: 6.860

View more
  3 in total

1.  Recurrent Glomerular Disease after Kidney Transplantation: Diagnostic and Management Dilemmas.

Authors:  Audrey Uffing; Frank Hullekes; Leonardo V Riella; Jonathan J Hogan
Journal:  Clin J Am Soc Nephrol       Date:  2021-10-22       Impact factor: 8.237

2.  Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group.

Authors:  Andrea Havasi; Cihan Heybeli; Nelson Leung; Avital Angel-Korman; Vaishali Sanchorawala; Oliver Cohen; Ashutosh Wechalekar; Frank Bridoux; Insara Jaffer; Victoria Gutgarts; Hani Hassoun; Maya Levinson; Cara Rosenbaum; Paolo Milani; Giovanni Palladini; Giampaolo Merlini; Ute Hegenbart; Stefan Schönland; Kaya Veelken; Alexander Pogrebinsky; Gheorghe Doros; Heather Landau
Journal:  Blood Cancer J       Date:  2022-08-18       Impact factor: 9.812

Review 3.  Amyloidosis of the Heart and Kidney.

Authors:  Horacio E Adrogue
Journal:  Methodist Debakey Cardiovasc J       Date:  2022-09-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.